Linda J. Burns, MD, on a Phase II Study of ACE-536 in Beta-Thalassemia
2014 ASH Annual Meeting2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 53, “ACE-536 Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults With Beta-Thalassemia: Preliminary Results From a Phase II Study,” presented by Antonio G. Piga, MD.
Related Videos
Laurie Sehn, MD, on Lenalidomide Plus Rituximab in Previously Untreated Mantle Cell Lymphoma
Laurie Sehn, MD, of the BC Cancer Agency, on abstract 625, “Sustained Remission With the Combin...
Richard M. Stone, MD, on the UK NCRI AML17 Trial
Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract 7,
James O. Armitage, MD, FACP, FRCP, and Bertrand Coiffier, MD, PhD, on Managing Lymphoma: The French Perspective
James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Bertrand Coiffier, MD, PhD, of the Centre Hospitalier Lyon-Sud discuss three F...
Laurie Sehn, MD, on Brentuximab Vedotin in Diffuse Large B-Cell Lymphoma With Undetectable CD30
Laurie Sehn, MD, of the BC Cancer Agency, on abstract 629, “Brentuximab Vedotin Monotherapy in ...
James O. Armitage, MD, FACP, FRCP, and Hagop M. Kantarjian, MD, on Advances in the Treatment of ALL
James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Hagop M. Kantarjian, MD, of The University of Texas MD Anderson Cancer Center,...
